Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10936)	11/10/1997 9:09:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 32384

<<<<<<PHASE II/III Data Are Favorable for Ligand's Targretin(TM) Capsules ..thanks again .......correct me if i am wrong. but, it appears that the response with CTCL would make ligand a likely candidate for cocktail use with other medications. as this seems to be a more common therapy with many types of cancers and especially aids, it would appear that approval by fda would be likely. ......i always assume that medication for cancer receives preferential treatment by fda if it may alleviate suffering in even small groups of uncurable populations.